Konstantinopoulos, P. A., Barry, W. T., Birrer, M., Westin, S. N., Cadoo, K. A., Shapiro, G. I., . . . Matulonis, U. A. (2019). Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: A dose-escalation and dose-expansion phase 1b trial. Lancet Oncol.
Citación estilo ChicagoKonstantinopoulos, Panagiotis A., et al. "Olaparib and α-specific PI3K Inhibitor Alpelisib for Patients With Epithelial Ovarian Cancer: A Dose-escalation and Dose-expansion Phase 1b Trial." Lancet Oncol 2019.
Cita MLAKonstantinopoulos, Panagiotis A., et al. "Olaparib and α-specific PI3K Inhibitor Alpelisib for Patients With Epithelial Ovarian Cancer: A Dose-escalation and Dose-expansion Phase 1b Trial." Lancet Oncol 2019.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.